MedKoo Biosciences

Kobe0065
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406531

CAS#: 436133-68-5

Description: Kobe0065 is a small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Kobe0065 binds to Ras-GTP, blocking interactions with Raf kinase. Kobe0065 inhibits anchorage-dependent and -independent growth, blocks MEK/ERK activity and induces apoptosis in H-rasG12V transformed NIH3T3 cells. Kobe0065 also inhibits tumor growth in SW480 colon cancer cell xenografts.

Chemical Structure

Kobe0065

CAS# 436133-68-5

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 406531
Name: Kobe0065
CAS#: 436133-68-5
Chemical Formula: C15H11ClF3N5O4S
Exact Mass: 449.02
Molecular Weight: 449.790
Elemental Analysis: C, 40.05; H, 2.46; Cl, 7.88; F, 12.67; N, 15.57; O, 14.23; S, 7.13

Price and Availability

Size	Price	Availability
10mg	USD 110	Ready to ship
25mg	USD 220	Ready to ship
50mg	USD 400	Ready to ship
100mg	USD 650	Ready to ship
200mg	USD 1050	Ready to ship
500mg	USD 1850	Ready to ship
1g	USD 2850	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Kobe0065; Kobe 0065; Kobe0065.

IUPAC/Chemical Name: N-(3-chloro-4-methylphenyl)-2-(2,6-dinitro-4-(trifluoromethyl)phenyl)hydrazinecarbothioamide.

InChi Key: KSJVAYBCXSURMQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H11ClF3N5O4S/c1-7-2-3-9(6-10(7)16)20-14(29)22-21-13-11(23(25)26)4-8(15(17,18)19)5-12(13)24(27)28/h2-6,21H,1H3,(H2,20,22,29)

SMILES Code: FC(C1=CC([N+]([O-])=O)=C(NNC(NC2=CC=C(C)C(Cl)=C2)=S)C([N+]([O-])=O)=C1)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Kobe0065 is an inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46±13 μM.
In vitro activity:	This study first examined the effect of Kobe0065, the most potent inhibitor among the Kobe0065-family compounds, on LOX (lysyl oxidase) expression in three human cancer cell lines, SW620 carrying the K-rasG12V, Panc-1 carrying the K-rasG12D and BxPC-3 carrying the wild-type ras in 2D culture. These cell lines showed high expression of 46-kDa prepro-LOX, which was effectively downregulated by treatment with 20 μM Kobe0065 in SW620 and Panc-1 but not BxPC-3 (Fig. 1A). Reference: Cancer Lett. 2017 Dec 1;410:82-91. https://pubmed.ncbi.nlm.nih.gov/28951129/
In vivo activity:	The antitumour activity of GA (glycyrrhetinic acid) was assessed using a xenograft of A549 cells in nude mice. The tumour size of the model group displayed a significant increase compared with the GA-treated mice (Fig. 5A and B). A high dose of GA inhibited tumour growth by 50%–60%, similar to animals treated with Kobe (Kobe0065). For the histological analysis, tumour tissue sections were stained with haematoxylin & eosin (H&E). Compared with the model group, the high-dose GA and Kobe groups exhibited an obviously ameliorated severity of necrosis and pyknosis in the nuclei of tumour cells. Reference: Acta Pharm Sin B. 2019 Mar; 9(2): 294–303. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438844/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	50.5	112.27
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.11
	DMF	10.0	22.23
	Ethanol	9.0	20.01

Preparing Stock Solutions

The following data is based on the product molecular weight 449.790000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Yoshikawa Y, Takano O, Kato I, Takahashi Y, Shima F, Kataoka T. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway. Cancer Lett. 2017 Dec 1;410:82-91. doi: 10.1016/j.canlet.2017.09.017. Epub 2017 Sep 23. PMID: 28951129. 2. Zhang Y, Wang Z, Ma X, Yang S, Hu X, Tao J, Hou Y, Bai G. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B. 2019 Mar;9(2):294-303. doi: 10.1016/j.apsb.2018.11.002. Epub 2018 Nov 27. PMID: 30976491; PMCID: PMC6438844.
In vitro protocol:	1. Yoshikawa Y, Takano O, Kato I, Takahashi Y, Shima F, Kataoka T. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway. Cancer Lett. 2017 Dec 1;410:82-91. doi: 10.1016/j.canlet.2017.09.017. Epub 2017 Sep 23. PMID: 28951129.
In vivo protocol:	1. Zhang Y, Wang Z, Ma X, Yang S, Hu X, Tao J, Hou Y, Bai G. Glycyrrhetinic acid binds to the conserved P-loop region and interferes with the interaction of RAS-effector proteins. Acta Pharm Sin B. 2019 Mar;9(2):294-303. doi: 10.1016/j.apsb.2018.11.002. Epub 2018 Nov 27. PMID: 30976491; PMCID: PMC6438844.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Shima F, Yoshikawa Y, Ye M, Araki M, Matsumoto S, Liao J, Hu L, Sugimoto T, Ijiri Y, Takeda A, Nishiyama Y, Sato C, Muraoka S, Tamura A, Osoda T, Tsuda K, Miyakawa T, Fukunishi H, Shimada J, Kumasaka T, Yamamoto M, Kataoka T. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. doi: 10.1073/pnas.1217730110. Epub 2013 Apr 29. PubMed PMID: 23630290; PubMed Central PMCID: PMC3657810.

Your view history

Kobe0065 featured